Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Puts on good news lol
Have to find some way to increase the share price, can't listen to the analysts predictions
IMUX: However, it appears that their SHARES-SELLING business is doing just fine!!!
None of their clinical studies were successful, this was mostly the reason of the share price falling
Immunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing
October 10 2022 - 07:00AM
PR Newswire (US)
Alert
Print
Share On Facebook
NEW YORK, Oct. 10, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX) ("Immunic" or the "Company"), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced it has entered into a securities purchase agreement (the "Purchase Agreement") with select accredited investors and certain existing investors to issue and sell an aggregate of 8,696,552 shares of its common stock ("Common Stock") at a price of $4.35 per share, reflecting a 10% premium to the closing price on October 7, 2022 on NASDAQ, and pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 5,096,552 shares of Common Stock at a purchase price of $4.34 per pre-funded warrant share, through a private investment in public equity ("PIPE") financing. The Pre-Funded Warrants will have an exercise price of $0.01 per share of Common Stock, to be immediately exercisable and remain exercisable until exercised in full. Immunic anticipates the gross proceeds from the PIPE to be approximately $60.0 million, before deducting any offering related expenses. The financing is expected to close on October 12, 2022, subject to customary closing conditions.
SVB Securities is acting as lead placement agent and Piper Sandler is acting as placement agent in connection with the financing.
The oversubscribed financing includes participation from new and existing institutional investors, including Deep Track Capital, Commodore Capital, BVF Partners LP, RTW Investments, LP, Great Point Partners, Logos Capital, Vivo Capital, Invus, Adage Capital Partners LP, Parkman Healthcare Partners, and Sphera Healthcare.
"We are highly pleased that this group of renowned, high-quality investors has participated in the financing to support our clinical-stage development pipeline targeting chronic inflammatory and autoimmune diseases," commented Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic. "Most notably, later this month, we eagerly await the initial clinical activity data from part C of our phase 1 clinical trial of IMU-935, our highly potent and selective oral IL-17 inhibitor, in moderate-to-severe psoriasis patients."
The Company intends to use net proceeds from the financing to fund the ongoing clinical development of its three lead product candidates, vidofludimus calcium (IMU-838), IMU-935 and IMU-856, and for other general corporate purposes. The proceeds from this PIPE financing, combined with current cash, cash equivalents and marketable securities, is expected to fund operating and capital expenditures into the fourth quarter of 2024.
The securities to be sold in this PIPE financing, including the shares of Common Stock underlying the Pre-Funded Warrants, have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state or other applicable jurisdiction's securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions' securities laws. Pursuant to the Purchase Agreement, Immunic has agreed to file a registration statement with the U.S. Securities and Exchange Commission registering the resale of the shares of Common Stock sold in the PIPE financing and the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants. Any offering of the securities under the resale registration statement will only be made by means of a prospectus.
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, vidofludimus calcium (IMU-838), a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor ROR?/ROR?t, is targeted for development in psoriasis, and castration-resistant prostate cancer. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash,
$IMUX-Immunic Inc reports Q2 EPS (82c), consensus (68c)
Cash and cash equivalents as of June 30 were $87.2M, which does not include the approximately $42.2M raised in the equity offering on July 19. Management expects its current cash and cash equivalents to be sufficient to fund operations into 2023. "So far this year, we have made outstanding progress with both our selective oral DHODH inhibitor, IMU-838, as well as IMU-935, a highly potent and selective inverse agonist of the transcription factor ROR?t, enabling what we believe will be an eventful and potentially transformative first half of 2022. In particular, we anticipate five data read-outs from clinical trials within the next twelve months, and expect to begin our first phase 3 pro gram very soon. I want to congratulate our entire team for this remarkable momentum," stated Daniel Vitt, CEO and president of Immunic. "In June, we received U.S. Food and Drug Administration (FDA) clearance for our Investigational New Drug (IND) application for the phase 3 ENSURE program of IMU-838 in patients with relapsing-remitting multiple sclerosis (RRMS), and the supportive phase 2 CALLIPER trial in patients with progressive multiple sclerosis (PMS). Initiation of these trials in the second half of this year will mark a major milestone for our lead program. Additionally, we look forward to completing recruitment of our ongoing phase 2 CALDOSE-1 trial of IMU-838 in patients with ulcerative colitis (UC) during the second half of 2021, and reporting top-line data for this potential second key indication for IMU-838 in the first half of 2022."
The stock keeps going lower, when will it turn around, needs more solid news.
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced management's participation in the following industry and investor conferences in March:
March 8-9: 2nd Annual European HealthTech CEO Forum. Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will participate in the "Advanced Therapeutics Panel" as part of the "Pandemic Response Day" on Tuesday, March 9, at 1:30 pm CET (7:30 am ET) to discuss the potential of IMU-838 as a treatment option for COVID-19.
March 9-10: H.C. Wainwright Global Life Sciences Conference. Dr. Vitt will present a company overview at the conference. The presentation will be available for viewing beginning March 9, at 7:00 am ET. An audio webcast of the presentation will be available on the "Events and Presentations" section of Immunic's website at: ir.imux.com/events-and-presentations. An archived replay will be available on the company's website for a period of 90 days after the conference.
March 11: BioCapital Europe 2021. Dr. Vitt will present a company overview on Thursday, March 11, at 10:50 am CET (4:50 am ET).
March 15-17: 33rd Annual Roth Conference. Dr. Vitt will participate in the "Therapies and Vaccines in the Fight Against COVID-19" panel on Monday, March 15, at 3:00 pm ET. In addition, Dr. Vitt will present a company overview. The presentation will be available for viewing anytime during the conference. Audio webcasts of both the panel discussion and the presentation will be available on the "Events and Presentations" section of Immunic's website at: ir.imux.com/events-and-presentations. An archived replay will be available on the company's website for a period of 90 days after the conference.
March 22-25: BIO-Europe Spring® Digital. Members of Immunic's management and business development teams will attend this conference and host one-on-one partnering meetings. To schedule a meeting, please use the BIO-Europe partnering portal at: https://informaconnect.com/bioeurope-spring/access-event/.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, COVID-19, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor ROR?t, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. For further information, please visit: www.imux.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's participation in industry and investor conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources to meet business objectives and operational requirements, the fact that the results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on February 26, 2021, and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.
Contact Information
Immunic, Inc.
Jessica Breu
Head of Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 322 2216
immunic@rxir.com
US Media Contact
KOGS Communication
Edna Kaplan
+1 781 639 1910
kaplan@kogspr.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/immunic-inc-to-participate-in-industry-and-investor-conferences-in-march-301238220.html
SOURCE Immunic, Inc.
Get the Latest IMUX - Immunic, Inc. News & Updates!
IMUX Chart by TradingView
< Newer Post Older Post >
MARCH 04, 2021
Cowen 41st Annual Health Care Conference
https://ir.adctherapeutics.com/events-and-presentations/default.aspx
10th Annual SVB Leerink Global Healthcare Conference
Give a listen if you one $IMUX
Thursday, February 25, 2021
https://wsw.com/webcast/svbleerink47/register.aspx?conf=svbleerink47&page=imux&url=https://wsw.com/webcast/svbleerink47/imux/2693120
IMUX Immunic shares a 'bargain' ahead of 'derisking catalysts,' says Roth Capital
Roth Capital analyst Zegbeh Jallah keeps a Buy rating on Immunic with a $64 price target following the company's Q4 report. Immunic has "several derisking catalysts" during 2021, beginning with data in late March or early April from a new dose cohort of IMU-838 in relapsing-remitting multiple sclerosis to support a successful end-of-Phase 2 meeting and Phase 3 study start in the second half of the year, Jallah tells investors in a research note. Data from IMU-838, IMU-935 and IMU-856 "could support a higher valuation for a stock already trading at a bargain," says Jallah. The analyst believes current valuation levels offer a "nice entry point."
IMUX Piper remains 'bullish' on Immunic progress with IMU-838 after Q4 update
Piper Sandler analyst Yasmeen Rahimi said following Immunic's earnings release that she remains "bullish" on the company's continued progress in its EMPhASIS program for IMU-838 for relapsing-remitting multiple sclerosis, or RRMS, which she views "as a key value driver for the stock." The analyst, who also views the company's opportunity in ulcerative colitis with IMU-838 as "significantly underappreciated," keeps an Overweight rating and $71 price target on Immunic shares.
Immunic updates make shares even more attractive, says Roth Capital
Roth Capital analyst Zegbeh Jallah keeps a Buy rating on Immunic with a $64 price target after the company presented detailed topline results from its Phase 2 CALVID-1 study of IMU-838 in hospitalized patients with moderate COVID-19 and new data for its Phase 2 investigator-sponsored study of IMU-838 in patients with primary sclerosing cholangitis. Both datasets are "supportive of continued development," Jallah tells investors in a research note. The analyst says that neither program is included in her model, creating "even more upside potential," in addition to a pipeline "that remains significantly undervalued."'
Two fairly good PR`s the past couple of days and stock sells off 20% alone today. Bought some trading shares close to lows as the selling stopped at the 1 year 200 day SMA which sits at $16.12.
Also today Piper 'encouraged' by Immunic datasets for IMU-838
After Immunic filed "an in-depth 8K" with a detailed analysis of the Phase 2 CALVID-1 and Phase 2 PSC studies of IMU-838, Piper Sandler analyst Yasmeen Rahimi said she is "encouraged by both datasets," adding that the topline data from the Phase 2 proof-of-concept study for IMU-838 in 11 primary sclerosing cholangitis, or PSC, "strong." The analyst, who continues to see multiple sclerosis and ulcerative colitis as Immunic's "key value drivers," also said she views COVID-19 and PSC as "call optionalities." Rahimi keeps an Overweight rating and $71 price target on Immunic shares.
Immunic: Competitive Phase 2 Data In Multiple Sclerosis
Jan. 24, 2021
https://seekingalpha.com/article/4400602-immunic-competitive-phase-2-data-in-multiple-sclerosis
Nice bump up in institutional ownership 3rd Q 2020, looking forward to Q 4 for update:
https://whalewisdom.com/stock/vtl-2
Haven't heard from you lastly, same thoughts about this stock?
Look at their pipeline!! Especially the drug.... that’s in phase 3 with the loan!!
IMUX $IMUX
Exactly it will be just like my BIIB when I bought it $103 and it practically tripled !!
IMUX will be. a MONSTER!!
Maverick
ALL in my opinion!
How would it outperform Biogen, since their price share is around the 260 level and considering IMUX is down again today.
They secured a LOAN for phase 3! They didn’t want to dilute and the after hours traders and market makers TANKED it 5% to $18 and change!
I am LONG FOREVER IN IMUX!
It’s going to outperform my BIIB
IMUX
$IMUX
Special thanks to CBBT $CBBT for being so gracious to contribute 200 more share to my IMUX!
8,300 shares and Long!! MULTI BILLION MASSIVE POTENTIAL and LMAO at the traders selling it down because they were smart and got a loan instead of screwing shareholders!
Maverick
Ok, let’s see what we can add on my favorite BIO STOCK OF THE WHOLE WORLD!! IMUX
IMUX record!!! 2,000 shares for 8,100 total!! Share price is NOT even close to what it should be at $80 in my opinion! Here’s to continue talking to myself lol and accumulating the BEST BIO STOCK OUT THERE!!
All in my opinion!!
Thanks to INNO $INNO , HALB $HALB, ENZC $ENZC record profits these past few days for 2 ,000 precious IMUX $IMUX SHARES!!
Yahoo!!
Maverick
All in my humble opinion!
Woohoo!! So HAPPY for us and all IMUX holders! Bring on $80 within a year!!
IMUX
$IMUX
Maverick
All in my humble opinion!
Twenty was broken today, Go IMUX
IMUX $IMUX Come on lets break $20 this week!!
GO IMUX $IMUX!!!
Maverick
All in my humble opinion!
IMUX $IMUX added 200 more shares today!! Thanks ENZC $ENZC!!!
6,100 shares and very undervalued!!!!
Maverick
All in my humble opinion!
IMUX $IMUX added 400 more shares today thanks to ENRT $ENRT!
Best. Biopharma stock out there!
IiMUX now 5,900 shares and 59% to my goal of 10,000 shares!
Very undervalued!
All in my humble opinion!
Maverick
IMUX $IMUX Most undervalued Biopharma imho! Added 300 more share....
5,500 and counting!!
Go IMUX~~!!!
Maverick
All in my humble opinion!
THANKS FPVD $FPVD for a thousand More shares of my IMUX!,
5,200 shares and love the OTC to get more shares!,,
All in my humble opinion!
IMUX $IMUX
$80-$100 stock trading shares for 20% of their value in my humble opinion!
Maverick
What are your main reasons to like this stock, I been owning shares since the VTL conversion time frame.
PROUD IMUX $IMUX owner...... added another 200 shares Thanks to my $DSGT DSGT trades!
That’s why I LOVE THE OTC!
I trade lots of momo stocks, and then buy great companies on the big boards!
4,200 shares STRONG IMUX,
5,800 shares to go!,
So undervalued here it’s sick!
All in MY HUMBLE OPINION!
Maverick
IMUX—. $IMUX. GOING to daytrade and flip other runners to accumulate this puppy!
Goal is 200-300 IMUX shares a week.
Long 4,000 shares.
Very undervalued!
Goal 10,000 shares by end of year!
All in my humble opinion!
IMUX
$IMUX
IMUX , 200 more shares!!
Flash Friday sales!!
4,000 now!
IMUX
$IMUX
IMUX $IMUX!! Another 300 shares for 3,800 IMUX! Tucked away for proper valuation and like no term capital gains!
All in my opinion!
Let's hope that will happen, waiting for them to have solid news reports about their drug trials, nothing concrete yet.
IMUX $IMUX expect to see the stock double within 12 months, if not sooner! Love trading other stocks to continue building this puppy out!!
Added 300 more shares... 3,500 for the treasure chest, tucked away for long term capital gains in the future!!
GLTA!!!
Go IMUX $IMUX
Added 200 more today!!
3,200 strong!
IMUX
$IMUX
200 more... 3,000 IMUX STRONG!!
$IMUX
DCA dollar cost average down!!! Go IMUX!!!
Added 300 more shares!!
2,800 and counting!!!
Go IMUX
$IMUX
ON sale today, added another 500 shares!!! 2,500 and continuing to add on dips!!
Nice channel here!
IMUX
$IMUX
I used small portion of FORWARD SPLIT TSLA $TSLA shares to scoop another 1,000 shares!!
IMUX
$IMUX
I KNOW WE HAVE A HUGE WINNER HERE!
TSLA, AAPL, VFF, IMUX, VCEL,ATOM, GRWG, HTBX , GEVO and others for my “ normal portfolio”
I trade pennies, and when. I make bank get into these to diversify etc.
My goal is to have 10,000 IMUX by years end.
I thank goodness for pennies to trade allowing ME TO get nice positions in the above over the years!
Have a nice evening!
Nice work, low float this will move.fast and very healthy for our "normal portfolio"....
Looking forward big-time to the next update
IMUX $IMUX grabbed another 1,000 shares for 2,000 shares total!!
Followers
|
12
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
149
|
Created
|
04/15/19
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |